Drug intelligence / Profile preview

GTC-6000

Development stage: Unknown
Lead developer: Gismo Therapeutics
Modality: Small Molecules

Overview

GTC-6000 is a small molecule drug under development by Gismo Therapeutics. It acts as a modulator of microtubule-associated protein tau (TAU), targeting tau pathology implicated in neurodegenerative diseases. The primary therapeutic focus for GTC-6000 is on nervous system diseases, specifically Alzheimer’s disease and frontotemporal dementia. As of the latest update, its highest global R&D status is at the Discovery stage[1].

Targets

MAPT (Microtubule-associated protein tau)Aβ (Amyloid-beta peptides and aggregates)

Beyond the preview

Go deeper on GTC-6000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GTC-6000.

Explore the full profile